title: Chronic kidney disease after hematopoietic cell transplantation: frequency, risk factors, and outcomes.
abstract: BACKGROUND
  Occurrence of chronic kidney disease (CKD) after hematopoietic cell transplantation (HCT) is rare with relatively few reported cases. The aim of this study was to evaluate the frequency of CKD among patients who received HCT for hematologic and nonhematologic disorders.
  
  
  OBJECTIVE
  We performed a prospective study to evaluate the frequency of CKD and its risk factors. Between 1997 and 2006 there were 1693 patients engrafted at the Bone Marrow Transplant Research Center.
  
  
  METHODS
  CKD was defined as a doubling of serum creatinine level from the baseline and after 1 year from receiving a transplantation. The risk of CKD in relation to a non-based total body irradiation conditioning regimen, the type of graft (allograft autograft), and the incidences of graft-versus-host disease (GVHD), drug toxicity, and veno occlusive disease (VOD) were examined in 1963 HCT patients.
  
  
  RESULTS
  Kidney involvement developed in 66 patients (4%). By 6-12 months after HCT, approximately 33% of these patients developed CKD (23 patients: 19 allograft and 4 autograft). In most CKD patients, the cause was idiopathic. In 23 patients who developed CKD, 5 patients had acute kidney injury during the transplantation period with GVHD. Other renal involvements were as follows: hypertension (17%), proteinuria (15%), hydronephrosis (2%), hematuria (18%), and diabetes (3%).
  
  
  CONCLUSIONS
  The frequency of CKD in this study seems to be high. It is important to know the specific type of kidney damage, to determine when to be aware of the time of occurrence of renal complications and to understand the best methods to treat patients with renal injury secondary to nephrotic syndrome and idiopathic CKD.
authors.affiliation: Nephrology and Bone Marrow Transplant Research Center, Dr Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. saddadi_md@yahoo.com
authors.forename: F
authors.initials: F
authors.lastname: Saddadi
authors.forename: M
authors.initials: M
authors.lastname: Hakemi
authors.forename: I
authors.initials: I
authors.lastname: Najafi
authors.forename: K
authors.initials: K
authors.lastname: Moghadam
authors.forename: A
authors.initials: A
authors.lastname: Ghavamzadeh
authors.forename: M
authors.initials: M
authors.lastname: Jahani
authors.forename: M
authors.initials: M
authors.lastname: Ganji
authors.forename: M
authors.initials: M
authors.lastname: Amini
authors.forename: T
authors.initials: T
authors.lastname: Soleimanian
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007674:Kidney Diseases / Q000453:epidemiology*; D007676:Kidney Failure, Chronic / Q000453:epidemiology*; D008875:Middle Aged; D016017:Odds Ratio; D011446:Prospective Studies; D012189:Retrospective Studies; D012307:Risk Factors; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome